Application 214860
- Type
- NDA
- Sponsor
- ACER THERAPEUTICS INC
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | OLPRUVA | SODIUM PHENYLBUTYRATE | SUSPENSION;ORAL | 2G | Yes | No |
| 002 | OLPRUVA | SODIUM PHENYLBUTYRATE | SUSPENSION;ORAL | 3G | Yes | No |
| 003 | OLPRUVA | SODIUM PHENYLBUTYRATE | SUSPENSION;ORAL | 4G | Yes | No |
| 004 | OLPRUVA | SODIUM PHENYLBUTYRATE | SUSPENSION;ORAL | 5G | Yes | No |
| 005 | OLPRUVA | SODIUM PHENYLBUTYRATE | SUSPENSION;ORAL | 6G | Yes | No |
| 006 | OLPRUVA | SODIUM PHENYLBUTYRATE | SUSPENSION;ORAL | 6.67G | Yes | No |
| 007 | OLPRUVA | SODIUM PHENYLBUTYRATE | FOR SUSPENSION;ORAL | 0.5GM/PACKET | Yes | No |
| 008 | OLPRUVA | SODIUM PHENYLBUTYRATE | FOR SUSPENSION;ORAL | 1GM/PACKET | Yes | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 72542-200 | OLPRUVA | sodium phenylbutyrate | Acer Therapeutics Inc. | NDA | Current |
| 72542-300 | OLPRUVA | sodium phenylbutyrate | Acer Therapeutics Inc. | NDA | Current |
| 72542-400 | OLPRUVA | sodium phenylbutyrate | Acer Therapeutics Inc. | NDA | Current |
| 72542-500 | OLPRUVA | sodium phenylbutyrate | Acer Therapeutics Inc. | NDA | Current |
| 72542-600 | OLPRUVA | sodium phenylbutyrate | Acer Therapeutics Inc. | NDA | Current |
| 72542-667 | OLPRUVA | sodium phenylbutyrate | Acer Therapeutics Inc. | NDA | Current |
Documents#
Document, Submission type, Date table| Document | Submission type | Date |
|---|
| 83756 | SUPPL | 2025-10-15 |
| 83729 | SUPPL | 2025-10-14 |
| 75602 | ORIG | 2023-09-29 |
| 73042 | ORIG | 2022-12-27 |
| 73027 | ORIG | 2022-12-23 |